MedTrace Logo

Current Treatment of HCV Infection After HSCT

NCT03014986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2021-01-14

No results posted yet for this study

Summary

The availability of novel therapies with DAAs might prompt clinicians caring for HSCT recipients with HCV infection to prescribe the treatment more frequently and possibly earlier after HSCT. Since numerous possible therapeutic combinations exist, the choice of the most appropriate one is not straightforward. It depends not only on its efficacy, toxicity and rate of pharmacological interactions, but also on availability (both through healthcare system and in expanded access programs), and cost.

This observational prospective study will focus on treatment strategies in HSCT recipients with HCV infection. The main focus will be the therapeutic approach, the combination of drugs chosen, the length of treatment and the outcome. The main reasons for treating or not treating HSCT recipients with HCV infection will be also explored. Compared to previous cohorts, this study might provide additional data in the area of non-invasive assessment of fibrosis, HCV-RNA levels and genotyping.

In order to get as much data as possible on HCV treatment, patients with chronic HCV infection transplanted during the last 10 years will be included.

Finally the prevalence of HCV-RNA positive patients among those transplanted in the year 2016 will be reported.

Conditions

  • Hepatitis C

Sponsors & Collaborators

  • European Society for Blood and Marrow Transplantation

    lead NETWORK

Principal Investigators

  • Simone Cesaro · Paediatric Haematology Oncology, Policlinico G.B. Rossi

  • Malgorzata Mikulska · University of Genoa, San Martino University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-03-31
Completion
2020-07-31

Countries

  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03014986 on ClinicalTrials.gov